The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
344
Administered SC
B. J. Medical College & Civil Hospital
Ahmedabad, India
V.S. General Hospital
Ahmedabad, India
Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
Time frame: Baseline through Week 46
Percentage of Participants with ≥5% Body Weight Reduction
Time frame: Week 46
Percentage of Participants with Hemoglobin A1c (HbA1c) <7.0% in Participants with Type 2 Diabetes
Time frame: Week 46
Change from Baseline in Waist Circumference in Participants with Obesity or Overweight
Time frame: Baseline, Week 46
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Gujarat Endocrine Center
Ahmedabad, India
Jawahar Lal Nehru Medical College
Ajmer, India
Motilal Nehru Medical College Hospital
Allahābād, India
Lifecare Hospital and Research Centre
Bengaluru, India
AIIMS, Bhubaneshwar
Bhubaneswar, India
Sri Ramachandra MedicaL College & Research Institute
Chennai, India
Kovai Diabetes Speciality Center and Hospital
Coimbatore, India
Apollo Excelcare Hospital
Guwahati, India
...and 11 more locations